---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000046"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-07-28T23:59:59+00:00"
generated_at: "2026-06-12T23:20:42.185679+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA refuses troriluzole NDA for SCA; BHV-7000 EEG data positive

## Summary
- FDA refused to file troriluzole NDA for SCA because primary endpoint not met; company may request Type A meeting within 30 days.
- BHV-7000: preliminary EEG data shows target engagement with no somnolence/fatigue; pivotal studies in epilepsy/bipolar disorder planned for 2H2023.
- BHV-8000 Phase 1: three dose cohorts dosed, well tolerated, achieved projected therapeutic concentrations; Phase 2 in Parkinson's planned for 2024.
- BHV-1300 bispecific IgG degrader advancing to IND in 2H2023; competitive safety and manufacturing profile.
- Once-daily extended-release formulation for BHV-7000 confirmed for Phase 2/3 programs.

## SEC filing metadata
- accession: 0001935979-23-000046
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-07-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000046/0001935979-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000046/bhvn-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000046
- JSON: https://secwatch.observer/filing/0001935979-23-000046.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.